Congenital malformations, deformations and chromosomal abnormalities in patients with T2DM and TUD (without obesity) (Comparision between matched semaglutide vs other anti-diabetes medications cohorts)

Size/cohort	Exposure	Comparison	cases (overall risk) (Exposure)	cases (overall risk) (Comparison)	RD (95% CI)		HR (95% CI)
1,302	semaglutide	insulins	34 (2.6%)	39 (3.0%)	-0.4% (-1.7%, 0.9%)	- ■ 	0.78 (0.49–1.23)
1,305	semaglutide	metformin	34 (2.6%)	34 (2.6%)	0.0% (-1.2%, 1.2%)	├	0.97 (0.60–1.56)
1,283	semaglutide	DPP-4i	33 (2.6%)	44 (3.4%)	-0.9% (-2.2%, 0.5%)	⊢	0.73 (0.47–1.15)
1,293	semaglutide	SGLT2i	34 (2.6%)	45 (3.5%)	-0.9% (-2.2%, 0.5%)	├──	0.72 (0.46–1.13)
1,292	semaglutide	SU	32 (2.5%)	26 (2.0%)	0.5% (-0.7%, 1.6%)	├	1.20 (0.72–2.02)
1,033	semaglutide	TZD	26 (2.5%)	12 (1.2%)	1.4% (0.2%, 2.5%)	-	2.07 (1.04–4.09)
1,268	semaglutide	other GLP-1RAs	31 (2.4%)	26 (2.1%)	0.4% (-0.8%, 1.5%)	├	1.15 (0.68–1.94)
					C	0.300.40	